This is a single arm dose escalation study of recombinant human keratinocyte growth factor
given to patients undergoing allogeneic bone marrow transplantation who are at high risk for
graft versus host disease (GVHD).
Completion date provided represents the completion date of the grant per OOPD records
Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6
HLA idential sibling donor